Our Take
A $2.5B company offering $50 in crypto for biometric data has discovered that people don't want to trade iris scans for speculative tokens—and regulators agree.
Why it matters
Tools for Humanity's stumble reveals the gap between venture appetite for identity tech and actual user willingness. For practitioners betting on biometric verification or crypto incentives as market drivers, this is a data point: regulatory bans (Kenya) and fines (South Korea, $830K) predict revenue shortfalls.
Do this week
Identity engineers: audit your consent funnel and regulatory footprint in each jurisdiction before scaling iris or facial capture beyond pilot stage.
Tools for Humanity lays off staff as revenue fails to materialize
Tools for Humanity, the identity verification startup chaired by OpenAI CEO Sam Altman, is conducting layoffs, according to Business Insider reporting. The company, known for its iris-scanning World device and associated Worldcoin cryptocurrency, is downsizing as it struggles to generate revenue (company-reported situation, not confirmed by the startup itself at time of reporting).
The company has attracted capital at a $2.5 billion valuation from investors including Andreessen Horowitz and Bain Capital. In the U.S., it has secured partnerships with Tinder, Zoom, and Docusign. But internationally, the model has cracked under regulatory and public pushback.
In Kenya, India, and Hong Kong, Tools for Humanity offered roughly $50 in Worldcoin (the company's cryptocurrency) in exchange for iris scans. Kenya subsequently banned World from operating in the country, citing privacy and financial concerns. South Korea fined the company $830,000 for alleged violations of local privacy law. The regulatory friction has translated into severely limited addressable market outside North America.
The timing compounds Altman's optics challenge: OpenAI announced a confidential IPO filing on Monday, the same week the layoffs at Tools for Humanity became public. The contrast is stark: one Altman venture is heading toward potential valuations in the hundreds of billions; the other is shrinking as it struggles to prove the core thesis that users will monetize their biometric data.
Biometric identity verification has a monetization problem, not a technology one
The failure of Tools for Humanity is instructive because it separates genuine capability from sustainable demand. The technology works: iris scanning is mature, and the engineering is sound. The problem is structural. Users are unwilling to trade permanent biometric data for volatile cryptocurrency, and regulators are actively hostile to the arrangement.
This matters for anyone building identity or verification infrastructure. The lesson is not that biometrics are broken—it is that the incentive model was. Offering $50 in speculative tokens does not overcome the permanence of giving away your iris scan. And when regulatory bodies see a company explicitly incentivizing citizens to surrender biometric data in exchange for foreign crypto, they respond with bans and fines. South Korea's $830K penalty is not a fine; it is a price signal.
For venture-backed identity startups, the signal is clear: if your go-to-market depends on user willingness to commodify biometric data for financial gain, your addressable market will shrink faster than your burn rate. Tools for Humanity proved the model works at $2.5B valuation; the layoffs prove the model does not work at revenue.
Stop treating biometric incentive loops as demand validation
If you are building identity infrastructure that relies on user opt-in for biometric capture, do not assume that financial incentives move the needle beyond short-term enrollment spikes. Tools for Humanity had the capital, partnerships, and technology. It lacked the one thing venture cannot buy: user comfort with permanent data trade-offs.
Audit your consent model now. If it depends on paying users to participate, it will not survive regulatory scrutiny or the first decline in token value. If it depends on mandatory capture (employment, banking, government ID), regulatory risk is higher but demand is real. Know which one you are building before you raise at a $1B+ valuation.